Skip to main content

Table 3 Paclitaxel pharmacokinetics

From: A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer

Ganetespib (mg/m2)

Number

Cmax

Tmax

T1/2

AUC

CL

MRT

(ng/ml)

(hours)

(hours)

(h*ng/ml)

(L/h/m2)

(hours)

100

3

3340 ± 1270

0.8 ± 0.3

12.9 ± 0.4

5900 ± 1440

14.2 ± 3.5

8.5 ± 0.8

150

6

3750 ± 1370

1.0 ± 0.0

13.6 ± 3.3

6280 ± 1430

13.4 ± 3.2

9.0 ± 4.0

  1. Cmax maximum serum concentration, Tmax time of maximum serum concentration observed, T 1/2 half-life AUC area under the curve, CL clearance, MRT mean resident time
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us